Wed, November 30, 2022
[ 12:00 AM ] - WOPRAI
Wed, November 23, 2022
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
Thu, November 3, 2022
[ 12:00 AM ] - WOPRAI
Wed, September 7, 2022
[ 12:00 AM ] - WOPRAI
Tue, August 16, 2022
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
Mon, August 8, 2022
[ 12:00 AM ] - WOPRAI
Wed, August 3, 2022
[ 12:00 AM ] - WOPRAI
Mon, July 25, 2022
[ 12:00 AM ] - WOPRAI
Thu, July 14, 2022
[ 12:00 AM ] - WOPRAI
Tue, May 31, 2022
Wed, April 13, 2022
[ 12:00 AM ] - WOPRAI
Mon, April 4, 2022
[ 12:00 AM ] - WOPRAI
Mon, March 21, 2022
[ 12:00 AM ] - WOPRAI
Fri, December 3, 2021
Tue, August 3, 2021
[ 12:00 AM ] - WOPRAI
Thu, July 1, 2021
[ 12:00 AM ] - WOPRAI
Mon, March 8, 2021
[ 12:00 AM ] - WOPRAI
Wed, December 2, 2020
Mon, June 1, 2020
[ 12:00 AM ] - WOPRAI
Wed, April 1, 2020
[ 12:00 AM ] - WOPRAI
Thu, February 13, 2020
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
Wed, January 2, 2019
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
Amit Hazan Maintained (BVS) at Hold with Decreased Target to $2.5 on, Nov 30th, 2022
Amit Hazan of Goldman Sachs, Maintained "Bioventus Inc." (BVS) at Hold with Decreased Target from $13 to $2.5 on, Nov 30th, 2022.
Amit has made no other calls on BVS in the last 4 months.
There are 4 other peers that have a rating on BVS. Out of the 4 peers that are also analyzing BVS, 2 agree with Amit's Rating of Hold. Following are those relevant analyst calls for the last 4 months
- Alexander Nowak of "Craig-Hallum" Downgraded from Strong Buy to Hold on, Tuesday, November 22nd, 2022
- Kyle Rose of "Canaccord Genuity" Downgraded from Strong Buy to Hold on, Wednesday, November 9th, 2022
These are the ratings of the 2 analyists that currently disagree with Amit
- Drew Ranieri of "Morgan Stanley" Maintained at Buy with Decreased Target to $5 on, Thursday, November 10th, 2022
- Robbie Marcus of "JP Morgan" Downgraded from Buy to Sell on, Wednesday, November 9th, 2022
Contributing Sources